Samaritan's Alzheimer's Drug Registered as CAPROSPINOL; SP-233 (Caprospinol) is Believed to Exhibit Neuroprotective Properties

Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer
of innovative drugs, announced today it has received its unique CAS
Registry Number for the chemical substance in its Alzheimer's drug
SP-233. CAS Registry Numbers are used in reference works, databases,
and regulatory compliance documents, to identify substances without
the ambiguity of chemical nomenclature.
-0-
*T
    Substance ID:     Caprospinol
    CAS No.:          873956-96-8
*T
   Dr. Greeson, CEO of Samaritan Pharmaceuticals, stated, "We are
completely excited about SP-233 (Caprospinol) as a totally new
approach to treat Alzheimer's disease." Dr. Greeson continued, "We
have been aggressively pushing to file an investigational new drug
(IND) application for Caprospinol and this is one of the many
milestones we have had to achieve to get there."

   Samaritan Pharmaceuticals: "We LIV....to Save Lives."

   Samaritan Pharmaceuticals is a drug development company driven to
discover, develop, and commercialize, innovative therapeutics for
AIDS, Alzheimer's, Cancer and Heart disease. Samaritan, in
collaboration with Georgetown University, is advancing eight promising
compounds, out of its rich pipeline of 250 possible drug candidates,
all of which have the potential to create revenue-generating
opportunities. Additional information is at www.samaritanpharma.com.

   Disclaimer

   The company disclaims any information that is created by an
outside party and endorses only information that is communicated by
its press releases, filings and Website. This news release contains
forward-looking statements that reflect management's current beliefs
about the potential for its drug candidates, science and technology.
However, as with any biopharmaceutical under development, there are
significant risks and uncertainties in the process of development and
regulatory review. There are no guarantees that products will prove to
be commercially successful. For additional information about the
factors that affect the company's business, please read the company's
latest Form 10-K filed April 15, 2005. The company undertakes no duty
to update forward-looking statements.